September 2017

Further Research on the Drug-Drug Interaction Between Gemfibrozil and Repaglinide Presented

Author: Michael Millhollen Posted: 27 September 2017

Sekisui XenoTech scientists previously established a gemfibrozil/repaglinide DDI resulting in increased repaglinide and metabolite plasma exposure and a vectoral shift in elimination pathways from biliary to urinary excretion following administration of gemfibrozil in male Sprague-Dawley rats. In that study, negligible effects on liver enzyme activity were observed following gemfibrozil treatment, suggesting that the DDI in rats was unlikely to be caused by P450 or UGT inhibition. In the present study, the potential role of uptake transporter proteins in the interaction was explored in vitro...

Read more